INF904 is a promising oral, low molecular weight drug development candidate that targets the C5aR receptor with high affinity and selectivity. InflaRx is targeting complement-mediated, chronic auto-immune and inflammatory conditions where an oral small molecule is the preferred route of administration for patients.
IFX002 is an advancement of vilobelimab technology, currently in preclinical development. IFX002 is a highly potent anti-complement C5a antibody, binding to the same epitope of the C5a protein than vilobelimab. With a higher humanization grade, altered pharmacokinetic properties and a strong patent position IFX002 is well positioned as life-cycle management project for vilobelimab.